4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, and the Foundation Fighting Blindness (FFB), the world’s largest non-governmental source of research funding for inherited retinal degenerations (IRD) and dry age-related macular degeneration (AMD), today announced a partnership to develop intravitreal gene therapeutics for patients with these blinding conditions using 4DMT-proprietary AAV vectors.
Retina International is counting down to its World Congress 2018 which is now just eight months away! The RIWC takes place on the 10th and 11th of February 2018 in Auckland New Zealand.
This event will bring together some of the world’s foremost retinal scientists and clinicians along with the global leaders in patient advocacy and peer support. With a two day scientific programme covering the key developments in basic and clinical research as well as further information on therapeutic development it is an event not to be missed.
The Board of Directors and National Trustees of the Foundation Fighting Blindness (FFB ) are sharing a recent New York Times article featuring Gordon and Lulie Gund. The column, written by David Brooks, is focused on the power of philanthropy and the motivation of philanthropists. Being mentioned is a welcome and fitting tribute to the Gunds’ commitment to finding treatments and cures for inherited retinal disease (IRDs) through supporting research for more than four decades and it is also an opportunity to make more people aware of the work of FFB and its mission.
Retina France and Macula Retina Spain are pleased to announce the first Patient Congress on The Retina and Macula, which will take place in Seville, Spain on Friday 20th and Saturday 21st of October, 2017. This initiative was conceived In October 2016 by the team of Jacinto Zulueta of Macula Retina Spain and Retina France at an event organised by Retina International.
Retina International is delighted to announce that our MC member Mr. KP Tsang has been elected onto the Council of Rare Disease International (RDI). In this role he will represent patients living with rare diseases globally. His appointment follows an on-line election process, which ran from April 26 to May 9, 2017.
KP will officially take up his position on the council at the RDI Membership Meeting which takes place in Barcelona in June 2017.
The Organisation for Economic Co-operation and Development (OECD) is launching a new initiative to promote an international, high-level dialogue on access to innovative pharmaceuticals and sustainability of pharmaceutical spending.
The OECD is now running a public consultation to identify issues with the current system, to understand which topics are of most importance to stakeholders, to find out if there are any major differences in stakeholder views and canvass new ideas. The responses will be used to inform policy recommendations for governments of OECD Member countries.
Severe Vision Loss for Three Florida Women
A Cautionary Tale About the Need to Educate Patients and Advance Research to Produce Treatments with Proven Efficacy, Says Foundation Fighting Blindness
Pictured: Christina Fasser, President of Retina International and Dr. Dorothee Leroux, ERN-EYE Project Manager
‘No country can claim to have achieved universal healthcare if it has not adequately and equitably met the needs of those with rare diseases’
Helen Clark, Administrator of the UN Development Programme
Retina International, with the support of member organisations, has designed the following survey to gather information on the real life experience of Patients affected by Inherited Retinal Disease (IRDs) in accessing Genetic Testing services in their countries of residence. This will aid us in developing appropriate communication and educational materials for our community globally.
For further information email email@example.com
Click below to access the survey.